Search

Displaying results 1781 - 1790 of 10000 in total
  1. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

    Synonyms: Pkr-in-1
  2. Drug

    Penbutolol

    go.drugbank.com/drugs/DB01359
    ApprovedInvestigationalWithdrawn

    Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. … This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy.

    Categories: Beta Blocking Agents, Non-Selective
  3. Drug

    Ammonia

    go.drugbank.com/drugs/DB11118
    ApprovedInvestigational

    It is a colorless gas with a pungent smell, and become NH4, or ammonium ion, when in water. … It is present in normally present in all tissues constituting a metabolic pool, where it is mostly taken up by glutamic acid and take part in transamination and other reactions, including the synthesis

    Mixtures: Physician EZ Use Joint Tunnel and Trigger Kit, Physician EZ Use Joint Tunnel and Trigger Kit
  4. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644]. … Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK

  5. Drug

    Methylnaltrexone

    go.drugbank.com/drugs/DB06800
    ApprovedInvestigational

    Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. … FDA approved in 2008.

  6. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.

  7. Drug

    Acetyldigitoxin

    go.drugbank.com/drugs/DB00511
    Approved

    Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved. … Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]

  9. Drug

    Penicillium camemberti

    go.drugbank.com/drugs/DB10809
    Approved

    Penicillium camemberti extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureCategories: Non-Standardized Fungal Allergenic Extract
  10. Drug

    Penicillium roqueforti

    go.drugbank.com/drugs/DB10812
    Approved

    Penicillium roqueforti extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureCategories: Non-Standardized Fungal Allergenic Extract